News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
278,205 Results
Type
Article (22671)
Company Profile (57)
Press Release (255477)
Section
Business (76089)
Career Advice (719)
Deals (11426)
Drug Delivery (39)
Drug Development (39562)
Employer Resources (67)
FDA (6945)
Job Trends (6471)
News (134059)
Policy (12436)
Tag
Academia (2131)
Alliances (22968)
Alzheimer's disease (969)
Approvals (6894)
Artificial intelligence (72)
Bankruptcy (114)
Best Places to Work (5665)
Breast cancer (68)
Cancer (666)
Cardiovascular disease (57)
Career advice (623)
Cell therapy (119)
Clinical research (30493)
Collaboration (231)
COVID-19 (1633)
C-suite (55)
Cystic fibrosis (47)
Data (655)
Diabetes (61)
Diagnostics (3652)
Earnings (21623)
Employer resources (62)
Events (37333)
Executive appointments (153)
FDA (7257)
Funding (218)
Gene therapy (115)
GLP-1 (219)
Government (2293)
Healthcare (9112)
Infectious disease (1679)
Inflammatory bowel disease (68)
Interviews (101)
IPO (5360)
Job creations (993)
Job search strategy (554)
Layoffs (128)
Legal (1845)
Lung cancer (107)
Manufacturing (89)
Medical device (5185)
Medtech (5188)
Mergers & acquisitions (6124)
Metabolic disorders (171)
Neuroscience (1149)
NextGen Class of 2024 (2988)
Non-profit (3059)
Northern California (722)
Obesity (92)
Opinion (114)
Parkinson's disease (51)
Patents (45)
People (25849)
Phase I (9992)
Phase II (13966)
Phase III (9695)
Pipeline (245)
Policy (46)
Postmarket research (911)
Preclinical (4562)
Radiopharmaceuticals (106)
Rare diseases (135)
Real estate (2093)
Regulatory (8975)
Research institute (2095)
Resumes & cover letters (92)
Southern California (619)
Startups (1723)
United States (6459)
Vaccines (283)
Weight loss (52)
Date
Today (69)
Last 7 days (442)
Last 30 days (1877)
Last 365 days (17688)
2024 (16170)
2023 (19694)
2022 (24537)
2021 (27153)
2020 (26278)
2019 (21554)
2018 (16026)
2017 (14303)
2016 (13532)
2015 (15566)
2014 (11120)
2013 (9091)
2012 (9441)
2011 (9667)
2010 (8115)
Location
Africa (329)
Arizona (61)
Asia (15938)
Australia (3346)
California (1573)
Canada (502)
China (112)
Colorado (71)
Connecticut (73)
Europe (36008)
Florida (240)
Illinois (173)
Indiana (85)
Kansas (48)
Maryland (260)
Massachusetts (1203)
Michigan (56)
Minnesota (94)
New Jersey (500)
New York (507)
North Carolina (306)
Northern California (722)
Ohio (87)
Pennsylvania (399)
South America (417)
Southern California (619)
Texas (278)
Utah (54)
Washington State (146)
278,205 Results for "critical path institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
Critical Path Institute and Centogene N.V. are pleased to announce the signing of a Memorandum of Understanding to advance drug development for lysosomal diseases and improve the quality of life for those impacted by these conditions.
June 20, 2024
·
5 min read
C-Path Launches Clinical Trial Simulator for Duchenne Muscular Dystrophy Research
Critical Path Institute’s (C-Path) Duchenne Regulatory Science Consortium (D-RSC) is excited to announce the launch of a groundbreaking model-based Clinical Trial Simulator (CTS), specifically designed to improve design of efficacy studies for potential therapies for Duchenne muscular dystrophy (DMD).
March 28, 2024
·
4 min read
Gene Therapy
Vertex, CRISPR’s Casgevy Highlights Complex Path to Gene Therapy Profitability
No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy. Experts weigh in on the path to profit for the treatment and the therapeutic class in general.
September 11, 2024
·
7 min read
·
Annalee Armstrong
Business
C-Path Appoints Dr. Klaus Romero as New CEO
Critical Path Institute announced that Klaus Romero, M.D., M.S., FCP, has been named its new Chief Executive Officer.
January 9, 2024
·
4 min read
Policy
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q1 2024.
June 4, 2024
·
1 min read
Press Releases
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
November 18, 2024
·
8 min read
BioCapital
Westat Awarded Contract to Continue Supporting the PATH Study
The National Institutes of Health’s (NIH’s) National Institute on Drug Abuse (NIDA) and the U.S. Food and Drug Administration’s (FDA’s) Center for Tobacco Products (CTP) have announced the award of a third contract to Westat to continue to support the Population Assessment of Tobacco and Health (PATH) Study.
February 21, 2024
·
3 min read
Cardiovascular disease
Lilly Plots Path for Cholesterol Pill After Strong Mid-Stage Showing
Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop in the biomarker after 12 weeks.
November 19, 2024
·
2 min read
·
Tristan Manalac
Business
Bio-Path Holdings Reports First Quarter 2024 Financial Results
Bio-Path Holdings, Inc. announced its financial results for the first quarter ended March 31, 2024 and provided an update on recent corporate developments.
May 15, 2024
·
7 min read
Genetown
4D Path Announces New Data Highlighting Efficacy of the Q-Plasia OncoReader (QPOR™) Platform
4D Path is pleased to announce today new clinical data highlighted in two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 – June 4, 2024 at McCormick Place, Chicago.
May 30, 2024
·
4 min read
1 of 27,821
Next
